Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer

Human CLDN18.2 is highly expressed in a significant proportion of gastric and pancreatic adenocarcinomas, while normal tissue expression is limited to the epithelium of the stomach. The restricted expression makes it a potential drug target for the treatment of gastric and pancreatic adenocarcinoma,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Guoyun, Foletti, Davide, Liu, Xiaohui, Ding, Sheng, Melton Witt, Jody, Hasa-Moreno, Adela, Rickert, Mathias, Holz, Charles, Aschenbrenner, Laura, Yang, Amy H., Kraynov, Eugenia, Evering, Winston, Obert, Leslie, Lee, Chenyu, Sai, Tao, Mistry, Tina, Lindquist, Kevin C., Van Blarcom, Thomas, Strop, Pavel, Chaparro-Riggers, Javier, Liu, Shu-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557842/
https://www.ncbi.nlm.nih.gov/pubmed/31182754
http://dx.doi.org/10.1038/s41598-019-44874-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557842/
https://www.ncbi.nlm.nih.gov/pubmed/31182754
http://dx.doi.org/10.1038/s41598-019-44874-0

Ejemplares similares